Pfizer to acquire 9.9% stake in CStone for $200m
Pfizer has agreed to acquire a 9.9% stake in the Hong Kong-listed biopharmaceutical firm CStone Pharmaceuticals for $200m. The transaction is part of a strategic collaboration between CStone
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XPfizer has agreed to acquire a 9.9% stake in the Hong Kong-listed biopharmaceutical firm CStone Pharmaceuticals for $200m. The transaction is part of a strategic collaboration between CStone
Abbott has received CE Mark approval for its new generation FreeStyle Libre 3 system for continuous and real time glucose monitoring for people living with diabetes in Europe.
Pfizer has secured the US Food and Drug Administration (FDA) approval for XELJANZ (tofacitinib), in tablet and oral solution formulations, to treat a type of polyarticular course juvenile
GlaxoSmithKline (GSK) has received the US Food and Drug Administration (FDA) approval for Nucala (mepolizumab) to treat a type of Hypereosinophilic Syndrome (HES). The FDA indicated Nucala to
Gilead Sciences and Galapagos have secured the European Commission (EC) approval to market Jyseleca (filgotinib) 200mg and 100mg tablets, to treat a type of rheumatoid arthritis (RA). EC
Novavax, a biotech firm focused on vaccine development, has commenced its first Phase 3 trial to evaluate the efficacy, safety and immunogenicity of its potential Covid-19 vaccine candidate,
Dutch health technology firm Royal Philips has launched its advanced QuickClear mechanical thrombectomy system in the US market, after receiving 510(k) approval from the US FDA. The mechanical
Johnson & Johnson (J&J) has commenced a large-scale, international Phase 3 clinical trial, dubbed ENSEMBLE, to evaluate its single-shot Covid-19 vaccine candidate JNJ-78436735. Also known as Ad26.COV2.S, the
Bristol Myers Squibb and bluebird bio have secured the US Food and Drug Administration (FDA) Priority Review for idecabtagene vicleucel (Ide-cel) to treat a type of multiple myeloma
Swiss drugmaker Roche has completed a share purchase agreement to acquire Irish biotech company Inflazome, for an upfront payment of €380m. Under the terms of the agreement, the